Safe CRISPR-Cas9 Inhibition of HIV-1 with High Specificity and Broad-Spectrum Activity by Targeting LTR NF-κB Binding Sites

• Egile Nagusiak: Cheng-Han Chung (Egilea), Alexander G. Allen (Egilea), Andrew J. Atkins (Egilea), Neil T. Sullivan (Egilea), Greg Homan (Egilea), Robert Costello (Egilea), Rebekah Madrid (Egilea), Michael R. Nonnemacher (Egilea), Will Dampier (Egilea), Brian Wigdahl (Egilea)
• Formatua: Liburua
• Argitaratua: Elsevier, 2020-09-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Viral latency of human immunodeficiency virus type 1 (HIV-1) has become a major hurdle to a cure in the highly effective antiretroviral therapy (ART) era. The clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 system has successfully been demonstrated to excise or inactivate int...